BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 33098891)

  • 1. Cytokeratin profiles in pituitary neuroendocrine tumors.
    Asa SL; Mete O
    Hum Pathol; 2021 Jan; 107():87-95. PubMed ID: 33098891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Follicular cells in pituitary neuroendocrine tumors.
    Delfin L; Mete O; Asa SL
    Hum Pathol; 2021 Aug; 114():1-8. PubMed ID: 33991528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokeratins and lung carcinomas.
    Nhung NV; Mirejovský P; Mirejovský T; Melínová L
    Cesk Patol; 1999 Jul; 35(3):80-4. PubMed ID: 11038661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Cytokeratin expression in the epithelial cells of nasal polyp].
    Zhuo M; Yang J; Yang F; Lin X
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Aug; 16(8):397-8. PubMed ID: 12412423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors.
    Mete O; Kefeli M; Çalışkan S; Asa SL
    Mod Pathol; 2019 Apr; 32(4):484-489. PubMed ID: 30390035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
    Tamas EF; Epstein JI
    Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnostic value of cytokeratins expression in the renal parenchyma tumors.
    Alexa A; Baderca F; Lighezan R; Izvernariu D; Raica M
    Rom J Morphol Embryol; 2010; 51(1):27-35. PubMed ID: 20191116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cauda Equina Neuroendocrine Tumors: Distinct Epithelial Neuroendocrine Neoplasms of Spinal Origin.
    Asa SL; Mete O; Schüller U; Ramani B; Mirchia K; Perry A
    Am J Surg Pathol; 2023 Apr; 47(4):469-475. PubMed ID: 36543154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunocytochemical study of tissues from clinically normal dogs and of neoplasms, using keratin monoclonal antibodies.
    Sandusky GE; Wightman KA; Carlton WW
    Am J Vet Res; 1991 Apr; 52(4):613-8. PubMed ID: 1711298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of thyroid transcription factor 1, PE-10, and cytokeratins 7 and 20 in discriminating between primary lung carcinomas and metastatic lesions in fine-needle aspiration biopsy specimens.
    Chhieng DC; Cangiarella JF; Zakowski MF; Goswami S; Cohen JM; Yee HT
    Cancer; 2001 Oct; 93(5):330-6. PubMed ID: 11668468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant keratin expression is common in primary hepatic malignant vascular tumors: A potential diagnostic pitfall.
    Lee HE; Torbenson MS; Wu TT; Chandan VS
    Ann Diagn Pathol; 2020 Dec; 49():151589. PubMed ID: 32947230
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of keratin monoclonal antibodies MAK-6, AE1:AE3, and CAM-5.2.
    Listrom MB; Dalton LW
    Am J Clin Pathol; 1987 Sep; 88(3):297-301. PubMed ID: 2443001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokeratin subtyping in chordomas and the fetal notochord: an immunohistochemical analysis of aberrant expression.
    Naka T; Iwamoto Y; Shinohara N; Chuman H; Fukui M; Tsuneyoshi M
    Mod Pathol; 1997 Jun; 10(6):545-51. PubMed ID: 9195570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratin subsets and monoclonal antibody HBME-1 in chordoma: immunohistochemical differential diagnosis between tumors simulating chordoma.
    O'Hara BJ; Paetau A; Miettinen M
    Hum Pathol; 1998 Feb; 29(2):119-26. PubMed ID: 9490269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative expression study of four cytokeratins and p63 in squamous cell carcinoma of the tongue: suitability for sentinel node navigation surgery using one-step nucleic acid amplification.
    Yamauchi K; Fujioka Y; Kogashiwa Y; Kohno N
    J Clin Pathol; 2011 Oct; 64(10):875-9. PubMed ID: 21705376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytokeratin 8/18-negative somatotroph pituitary neuroendocrine tumours (PitNETs, adenomas) show variable morphological features and do not represent a clinicopathologically distinct entity.
    Soukup J; Cesak T; Hornychova H; Manethova M; Michnova L; Netuka D; Vitovcova B; Cap J; Ryska A; Gabalec F
    Histopathology; 2021 Sep; 79(3):406-415. PubMed ID: 33738859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-cytokeratin markers for rapid frozen section immunocytochemistry from head and facial Mohs cases of basal cell carcinoma: a comparison and evaluation to determine the marker of choice.
    Orchard GE; Wojcik K; Shams F; Georgaki E; Quaye CJ; Fernando P; Torres J; Ismail F; Shams M
    Br J Biomed Sci; 2015; 72(2):61-6. PubMed ID: 26126321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and extent of cytokeratin expression in paraganglioma: an immunohistochemical study of 60 cases from 5 anatomic sites and review of the literature.
    Dermawan JK; Mukhopadhyay S; Shah AA
    Hum Pathol; 2019 Nov; 93():16-22. PubMed ID: 31442521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The immunophenotype of ependymomas.
    Vege KD; Giannini C; Scheithauer BW
    Appl Immunohistochem Mol Morphol; 2000 Mar; 8(1):25-31. PubMed ID: 10937045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors.
    Ferrero M; Spyratos F; Le Doussal V; Desplaces A; Rouëssé J
    Cytometry; 1990; 11(6):716-24. PubMed ID: 1696538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.